Compare Globus Medical Inc. Class A Common Stock (GMED) vs NOV Inc. Common Stock (NOV) Price & Performance

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

NOV trades at $18.96, up 0.37% with a bearish technical signal from moving averages. The company reported mixed Q2 2026 results, beating EPS estimates but showing revenue decline. Valuation metrics show a high P/E ratio of 70.22 but attractive P/S of 0.81, while profitability remains weak with 1.1% net margin. Recent news highlights strong subsea demand but Middle East risks and weak equipment sales.

The outlook is cautious with analyst consensus at $21.80 target (15% upside) but technical weakness. Investment opportunity lies in energy equipment strength and margin improvements, while risks include geopolitical exposure, competitive pressures, and inconsistent earnings performance. The stock faces headwinds from capital spending constraints in the oilfield sector.